OTLK ▲ +3.2% - Outlook Therapeutics, Inc. $OTLK OTLKW - Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ Outlook Therapeutics rose 3.2% following news that it has appointed Kevin Lundquist as Chief Financial Officer as the company prepares for the U.S. commercial launch of its drug LYTENAVA™. The CFO appointment signals that Outlook is advancing toward a critical milestone in bringing the treatment to market, which likely bolstered investor confidence in management's ability to execute the commercialization strategy. 27-AUG-2026 04:06 PM ET